Valuable Insight : New EP Vantage report sees the number of immuno-oncology combination trials triple and Keytruda steal the crown from Opdivo

Please follow link to Evaluate GroupĀ and down load PDF report. http://www.evaluategroup.com/public/PressReleases/EPVantage-PD1-PDL1-Combination-Therapies-Revolution.aspx Enjoy the information /SvenĀ